Episode Description
Is the digital health IPO drought over? Halle and Michael dig into the Hinge Health IPO and what it signals for the return of digital health companies to the public markets. They explore how much equity founders typically hold at IPO, the growing role of private equity, and why down rounds arenāt the deal-breaker they once were.
Plus: Elizabeth Holmesā husband launches a head-scratching startup, a former McKinsey healthcare partner faces prison time, and OpenAI teams up with the FDA.
We cover:
š What Hinge Healthās IPO means for digital health exits
š A new analysis of founder equity and CEO pay at IPO
š¤ OpenAIās behind-the-scenes work with the FDA
āļø Why a startup is suing Epic for alleged anti-competitive behavior
š§Ŗ The eyebrow-raising new diagnostics startup from Elizabeth Holmesā husband
šØ The McKinsey partner sentenced in the opioid crisis investigation
ā
Show Notes
- How Much Equity Do Founders Own at IPO? Read the full analysis on Substack
- Epic Faces Another Antitrust Lawsuit More on the Epic lawsuit via Fierce Healthcare
- OpenAI and the FDA Are Talking Drug Reviews Wiredās coverage of OpenAI-FDA discussions
- McKinsey Partner Sentenced in Opioid Probe NYT on McKinsey's legal fallout
ā
š If you're enjoying the show, please leave us a review!
ā
š Connect with us:
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.